SMT201600134B - Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. - Google Patents

Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.

Info

Publication number
SMT201600134B
SMT201600134B SM201600134T SM201600134T SMT201600134B SM T201600134 B SMT201600134 B SM T201600134B SM 201600134 T SM201600134 T SM 201600134T SM 201600134 T SM201600134 T SM 201600134T SM T201600134 B SMT201600134 B SM T201600134B
Authority
SM
San Marino
Prior art keywords
diamminopyrimidine
molted
fak
alk
double inhibitor
Prior art date
Application number
SM201600134T
Other languages
English (en)
Italian (it)
Inventor
Martin J Jacobs
Gregory R Ott
Laurent Courvoisier
Shawn P Allwein
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600134(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of SMT201600134B publication Critical patent/SMT201600134B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SM201600134T 2012-03-06 2016-05-10 Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. SMT201600134B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
SMT201600134B true SMT201600134B (it) 2016-07-01

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600134T SMT201600134B (it) 2012-03-06 2016-05-10 Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.

Country Status (28)

Country Link
US (5) US9132128B2 (OSRAM)
EP (2) EP3056494B1 (OSRAM)
JP (2) JP6016953B2 (OSRAM)
KR (1) KR102068374B1 (OSRAM)
CN (2) CN104159894B (OSRAM)
AU (1) AU2013229995B2 (OSRAM)
CA (1) CA2865420C (OSRAM)
CL (1) CL2014002353A1 (OSRAM)
CY (1) CY1117565T1 (OSRAM)
DK (1) DK2822939T3 (OSRAM)
EA (2) EA025859B1 (OSRAM)
ES (2) ES2570976T3 (OSRAM)
HR (1) HRP20160387T1 (OSRAM)
HU (1) HUE027976T2 (OSRAM)
IL (2) IL234239A (OSRAM)
ME (1) ME02460B (OSRAM)
MX (2) MX347772B (OSRAM)
MY (1) MY177290A (OSRAM)
NZ (1) NZ630251A (OSRAM)
PH (1) PH12014501979A1 (OSRAM)
PL (1) PL2822939T3 (OSRAM)
RS (1) RS54689B1 (OSRAM)
SG (2) SG10201507865QA (OSRAM)
SI (1) SI2822939T1 (OSRAM)
SM (1) SMT201600134B (OSRAM)
UA (1) UA115052C2 (OSRAM)
WO (1) WO2013134353A1 (OSRAM)
ZA (1) ZA201406147B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
MX2021001398A (es) 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5512274B2 (ja) * 2006-10-23 2014-06-04 セファロン、インク. ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
HUE046402T2 (hu) * 2009-06-10 2020-03-30 Chugai Pharmaceutical Co Ltd Tetraciklusos vegyületek
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
AU2013229995B2 (en) 2017-04-13
EP2822939A1 (en) 2015-01-14
EA201691574A1 (ru) 2017-03-31
CN106166155A (zh) 2016-11-30
CN106166155B (zh) 2019-01-18
HK1205119A1 (zh) 2015-12-11
SG11201405371PA (en) 2014-09-26
EA025859B1 (ru) 2017-02-28
ES2570976T3 (es) 2016-05-23
CA2865420A1 (en) 2013-09-12
CL2014002353A1 (es) 2015-01-09
SG10201507865QA (en) 2015-10-29
RS54689B1 (sr) 2016-08-31
US10111872B2 (en) 2018-10-30
IL234239A (en) 2017-06-29
EA201491641A1 (ru) 2015-04-30
CY1117565T1 (el) 2017-04-26
CN104159894A (zh) 2014-11-19
US20190328735A1 (en) 2019-10-31
MY177290A (en) 2020-09-10
HRP20160387T1 (hr) 2016-05-20
KR102068374B1 (ko) 2020-01-20
PH12014501979B1 (en) 2014-11-24
US10632119B2 (en) 2020-04-28
PH12014501979A1 (en) 2014-11-24
EP2822939B1 (en) 2016-02-17
AU2013229995A1 (en) 2014-09-25
MX347772B (es) 2017-05-12
US9339502B2 (en) 2016-05-17
PL2822939T3 (pl) 2016-08-31
HUE027976T2 (en) 2016-11-28
CN104159894B (zh) 2016-09-07
CA2865420C (en) 2020-06-02
US20170173017A1 (en) 2017-06-22
MX372740B (es) 2020-05-04
EP3056494B1 (en) 2018-05-02
KR20140138247A (ko) 2014-12-03
UA115052C2 (uk) 2017-09-11
JP2015509540A (ja) 2015-03-30
NZ630251A (en) 2016-02-26
ES2681487T3 (es) 2018-09-13
JP2017039741A (ja) 2017-02-23
US20160243119A1 (en) 2016-08-25
US20150374693A1 (en) 2015-12-31
IL252364B (en) 2018-03-29
MX2014010613A (es) 2014-09-18
ZA201406147B (en) 2015-12-23
WO2013134353A1 (en) 2013-09-12
SI2822939T1 (sl) 2016-04-29
US9623026B2 (en) 2017-04-18
EA033124B1 (ru) 2019-08-30
DK2822939T3 (en) 2016-03-14
WO2013134353A8 (en) 2014-06-19
US20150011561A1 (en) 2015-01-08
US9132128B2 (en) 2015-09-15
ME02460B (me) 2017-02-20
HK1226300A1 (zh) 2017-09-29
EP3056494A1 (en) 2016-08-17
JP6016953B2 (ja) 2016-10-26
IL252364A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
SMT201600134B (it) Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
HUE036259T2 (hu) Inhibitor vegyületek
SI3715345T1 (sl) Priprava zaviralca lfa-1
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
SMT201600114B (it) Inibitori di beta-secretasi
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
WO2014047502A3 (en) Anhydrous compositions having microcapsules and non-volatile oils
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
EP2840076A4 (en) BICYCLIC CONNECTION
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112014007719A2 (pt) proteases fúngicas
ME02985B (me) Prolekovi inhibitora amino-hinazolinske kinaze
EP2933248A4 (en) NOVEL RENIN INHIBITOR
SMT201600357B (it) Inibitori di iap
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
EP3082822A4 (en) Hiv protease inhibitors
ITTO20110268A1 (it) Composizione di maquillage.
EP3083609A4 (en) Hiv protease inhibitors
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
EP2875885A4 (en) Novel drill chuck
FR2959588B1 (fr) Condensateur auto-protege.
FR2991112B1 (fr) Laser semiconducteur optimise